Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This inform ....Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This information will provide the basis for tailoring treatment to a patients needs. It is anticipated that marketing of the PD GeneChip within Australia and overseas may produce revenue of at least $40 million annually.Read moreRead less
Quantitative measurement of Schizophrenia using Electrovestibulography. Schizophrenia was estimated to cost approximately $1.85billion in 2001 (0.3% of GDP and nearly $50k for each of the 37,000 Australians with the illness). Over one third of the cost is borne by sufferers and their carers. Misdiagnosis and incorrect therapy are common. To date quantitative assessment of Schizophrenics has been impossible making this tool potentially invaluable. An accurate diagnostic test could facilitate earl ....Quantitative measurement of Schizophrenia using Electrovestibulography. Schizophrenia was estimated to cost approximately $1.85billion in 2001 (0.3% of GDP and nearly $50k for each of the 37,000 Australians with the illness). Over one third of the cost is borne by sufferers and their carers. Misdiagnosis and incorrect therapy are common. To date quantitative assessment of Schizophrenics has been impossible making this tool potentially invaluable. An accurate diagnostic test could facilitate earlier diagnosis, more accurate treatment plans, and prevention of debilitating psychotic episodes for the sufferer. By being able to monitor drug efficacy the community can benefit by reduced drug costs, confinement times and hastened new drug development. Read moreRead less
Development of Novel Two-dimensional Techniques for Magnetic Resonance In-vivo Spectroscopy. Body chemistry alters with functionality, pain, ageing and disease. These changes can be recorded by magnetic resonance (MR) spectroscopy (MRS) in vivo in a whole body MR scanner. When changes in chemistry can be recorded rapidly, and the individual species assigned, it will be possible to make a definitive diagnosis and in some cases allow the tailoring of treatment on an individual basis. This is curre ....Development of Novel Two-dimensional Techniques for Magnetic Resonance In-vivo Spectroscopy. Body chemistry alters with functionality, pain, ageing and disease. These changes can be recorded by magnetic resonance (MR) spectroscopy (MRS) in vivo in a whole body MR scanner. When changes in chemistry can be recorded rapidly, and the individual species assigned, it will be possible to make a definitive diagnosis and in some cases allow the tailoring of treatment on an individual basis. This is currently hampered by our inability to separate the composite resonances in a one dimensional MR spectrum. Research will allow two dimensional MRS to be implemented and provide detailed chemical information on human organs in vivo. Read moreRead less